Analysts Set BridgeBio Pharma, Inc. (NASDAQ:BBIO) Target Price at $47.21
BridgeBio Pharma, Inc. (NASDAQ:BBIO – Get Free Report) has been given a consensus recommendation of “Buy” by the eleven ratings firms that are presently covering the firm, Marketbeat reports. One analyst has rated the stock with a hold recommendation, nine have assigned a buy recommendation and one has assigned a strong buy recommendation to the […]
More Stories
Fisher Asset Management LLC Has $1.66 Billion Holdings in Merck & Co., Inc. (NYSE:MRK)
Fisher Asset Management LLC lifted its position in shares of Merck & Co., Inc. (NYSE:MRK – Free Report) by 2.7%...
Morgan Stanley (NYSE:MS) Shares Bought by Fisher Asset Management LLC
Fisher Asset Management LLC lifted its stake in Morgan Stanley (NYSE:MS – Free Report) by 2.7% during the 3rd quarter,...
Independent Advisor Alliance Buys 10,484 Shares of Grayscale Bitcoin Trust (NYSEARCA:GBTC)
Independent Advisor Alliance grew its stake in Grayscale Bitcoin Trust (NYSEARCA:GBTC – Free Report) by 11.9% in the 3rd quarter,...
Exxon Mobil Co. (NYSE:XOM) Position Trimmed by Bedell Frazier Investment Counselling LLC
Bedell Frazier Investment Counselling LLC decreased its holdings in shares of Exxon Mobil Co. (NYSE:XOM – Free Report) by 0.5%...
iShares MSCI Emerging Markets ETF (NYSEARCA:EEM) is DRW Securities LLC’s 2nd Largest Position
DRW Securities LLC increased its holdings in shares of iShares MSCI Emerging Markets ETF (NYSEARCA:EEM – Free Report) by 603.8%...
Bedell Frazier Investment Counselling LLC Decreases Holdings in Align Technology, Inc. (NASDAQ:ALGN)
Bedell Frazier Investment Counselling LLC reduced its position in Align Technology, Inc. (NASDAQ:ALGN – Free Report) by 10.1% during the...